Analyst Reco. Alvotech

Equities

ALVO

LU2458332611

End-of-day quote Nasdaq Other stock markets 06:00:00 2024-05-14 pm EDT			5-day change	1st Jan Change
13.35 ^USD	0.00%		-1.84%	+16.29%

Apr. 30	Alvotech to Manufacture Humira Biosimilar for Quallent Pharmaceuticals	MT
Apr. 30	Alvotech to Make Humira Biosimilar Adalimumab-ryvk for Quallent	MT

Analyst Reco.

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Barclays Raises Price Target on Alvotech to $20 From $17, Maintains Overweight Rating	Mar. 22	MT
Barclays Upgrades Alvotech to Overweight From Equalweight, Raises Price Target to $17 From $10	Jan. 29	MT
Citigroup Upgrades Alvotech to Neutral From Sell, Adjusts Price Target to $10 From $5	23-10-20	MT
Barclays Initiates Alvotech With Equalweight Rating, Price Target is $10	23-09-21	MT
Deutsche Bank Adjusts Alvotech Price Target to $8 From $12, Maintains Hold Rating	23-06-30	MT
Deutsche Bank Adjusts Alvotech's Price Target to $12 From $8, Maintains Hold Rating	23-03-07	MT
Morgan Stanley Starts Alvotech at Equalweight With $10 Price Target	22-09-07	MT
Citigroup Double Downgrades Alvotech to Sell From Buy, Adjusts Price Target to $5 From $12	22-09-06	MT
Citigroup Starts Alvotech at Buy With $12 Price Target	22-07-26	MT
Deutsche Bank Initiates Coverage on Alvotech With Hold Rating, $10 Price Target	22-07-01	MT

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Filters

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.

BENEFIT NOW